AMLX Valuation

Amylyx Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

8.300

-0.09(-1.073%)1D

Overview
Forecast
Valuation
Earnings

AMLX Relative Valuation

AMLX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, AMLX is overvalued; if below, it's undervalued.

Historical Valuation

Amylyx Pharmaceuticals Inc (AMLX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 1.96. The fair price of Amylyx Pharmaceuticals Inc (AMLX) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：8.30

Fair

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

3.71

P/B

Median3y

3.97

Median5y

3.61

-32.53

FCF Yield

Median3y

-18.33

Median5y

-17.28

Competitors Valuation Multiple

The average P/S ratio for AMLX's competitors is 70.29, providing a benchmark for relative valuation. Amylyx Pharmaceuticals Inc Corp (AMLX) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

AMLX.O

Amylyx Pharmaceuticals Inc

Loss

Average P/S: 70.29

-100.00%